PureTech Health (LON:PRTC) Stock Price Down 12.4% – What’s Next?

PureTech Health plc (LON:PRTC) shares fell 12.4% during mid-day trading on Wednesday . The stock traded as low as GBX 100.40 ($1.31) and last traded at GBX 103 ($1.35). 3,018,245 shares changed hands during trading, an increase of 192% from the average session volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.54).

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 455 ($5.96) price objective on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Trading Up 14.6 %

The company’s 50 day simple moving average is GBX 135.24 and its 200 day simple moving average is GBX 148.08. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The firm has a market cap of £354.45 million, a price-to-earnings ratio of -4.84 and a beta of 1.02.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.